Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674465 · ClinicalTrials.gov registry record
Role of Nox2 in CNI-induced Renal Fibrosis
A clinical trial of Kidney Disease, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 8
- Enrollment target
- 2
- Study locations
NCT01674465: Completed study of Kidney Disease, sponsored by University of Wisconsin, Madison.
NCT01674465 is a study of Kidney Disease that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 8 participants, below the 2,940-participant average among 23 other Kidney Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01674465, a study of Kidney Disease, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
Calcineurin Inhibitors (CNI) are drugs used to suppress the immune system when a person has a solid organ transplant. Although these drugs keep the transplanted organ from being rejected they are toxic to kidneys, or nephrotoxic. CNIs cause damage, called fibrosis, to kidneys. Fibrosis is a type of scarring that occurs in kidney tissue. Fibrosis can eventually lead to kidney failure. One of the pathways that cause fibrosis is a chronic lack of oxygen to the kidney tissue called "hypoxia". There is a protein called Nox2 that may be involved in how this hypoxia happens in the kidney. The Department of Medicine-Nephrology at the University of Wisconsin is conducting a research study to see how much of the Nox2 protein is present in kidneys that may have fibrosis caused by CNIs and whether a certain type of Magnetic Resonance Imaging (MRI) can be used to tell in advance if the disease caused by CNIs is getting worse. Study hypothesis: MRI, a non-invasive technique, can be used to determine whether CNI induced kidney disease is getting worse. Additionally, the study aims to determine the role of Nox2 in CNI nephrotoxicity.
Primary Outcome
The Nox2 protein will be determined in subjects who are potentially have CNI nephrotoxicity
Conditions Studied
Interventions
- BIOLOGICAL Hypoxyprobe-1
Study Locations (2)
Wisconsin
- Wisconsin Institute for Medical Research (WIMR) - Madison
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-11-30 |
| Est. Completion | 2019-10-10 |
What the finished NCT01674465 record still lists
NCT01674465 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,940-participant average among 23 other Kidney Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Hypoxyprobe-1 is the first listed.
NCT01674465 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01674465 about?
NCT01674465 is a clinical study titled "Role of Nox2 in CNI-induced Renal Fibrosis". Calcineurin Inhibitors (CNI) are drugs used to suppress the immune system when a person has a solid organ transplant. Although these drugs keep the transplanted organ from being rejected they are toxic to kidneys, or nephrotoxic. CNIs cause damage, called fibrosis, to kidneys. Fibrosis is a type of...
What is the current status of trial NCT01674465?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-11-30. Estimated completion is 2019-10-10.
What conditions does trial NCT01674465 study?
This clinical trial studies the following conditions: Kidney Disease.
What interventions are being tested in trial NCT01674465?
The interventions under investigation include: Hypoxyprobe-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01674465?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01674465 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01674465's enrollment target sits among peer trials
8 24th of 23 the lowest of 23 other Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
-
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
RECRUITING · Phase 3
-
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
RECRUITING · Phase 2
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI